Contradiction between in vitro and clinical outcome: Intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia

Journal of Infection and Chemotherapy

Volumn 20, Issue 3, 2014, Pages 199-207

  Kohno, Shigeru ^a   Tateda, Kazuhiro ^b   Kadota, Jun Ichi ^c   Fujita, Jiro ^d   Niki, Yoshihito ^e   Watanabe, Akira ^f   Nagashima, Masahito ^g  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OITA UNIVERSITY   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

^e SHOWA UNIVERSITY   (Japan)

^f TOHOKU UNIVERSITY   (Japan)

^g PFIZER INC   (United States)

Author keywords

Community acquired pneumonia; Intravenous azithromycin; Macrolide resistant; Pneumococcal pneumonia; Streptococcus pneumoniae

Indexed keywords

AZITHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATION; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAEMOPHILUS; HUMAN; IN VITRO STUDY; JAPAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; PHASE 3 CLINICAL TRIAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VERY ELDERLY; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PNEUMONIA, PNEUMOCOCCAL; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903699307     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2013.10.010     Document Type: Article

References (26)

1. File TM. Community-acquired pneumonia. Lancet 2003;362: 1991-2001.
2. Miyashita N, Matsushima T, Oka M, Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med 2006;45: 419-28.
3. Ministry of Health, Labour, and Welfare of Japan. Population survey report http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai11/index. html; 2011.
4. Mandell LA, Wunderink RG, Anzueto A, Bartlet JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-72.
5. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45: 1721-9.
6. Isozumi R, Ito Y, Ishida T, Osawa M, Hirai T, Ito I, et al. Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan. J Clin Microbiol 2007;45: 1440-6.
7. Niki Y, Hanaki H, Yagisawa M, Kohno S, Aoki N, Watanabe A, et al. The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility. J Infect Chemother 2008;14: 279-90.
8. Qin L, Watanabe H, Yoshimine H, Guio H, Watanabe K, Kawakami K, et al. Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae isolated from patients with community-acquired pneumonia and molecular analysis of multidrug-resistant serotype 19F and 23F strains in Japan. Epidemiol Infect 2006;134: 1188-94.
9. Daneman N, McGeer A, Green K, Low DE, Tronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implication for patient management. Clin Infect Dis 2006;43: 432-8.
10. Klugman KP. Clinical impact of antibiotic resistance in respiratory tract infections. Int J Antimicrob Agents 2007;29(Suppl. 1):S6-10. (Pubitemid 46343595)
11. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echagüen A, Gareen IF, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35: 556-64.
12. Aoki K, Otake T, Yoshida Y, Minamiyama K, Imamura K. Postmarketing surveillance of azithromycin in adult patients. Jpn J Chemother 2005;53: 421-30.
13. Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin Infect Dis 2004;38: 99-103.
14. Bishai W. The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother 2002;49: 433-6.
15. Yanagihara K, Izumikawa K, Higa F, Tateyama M, Tokimatsu I, Hiramatsu K, et al. Efficacy of azithromycin in the treatment of community acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med 2009;48: 527-35.
16. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, et al. Clinical evaluation methods for antimicrobial agents to treat respiratory infections: Report of the Committee for Respiratory System, Japan Society of Chemotherapy. J Infect Chemother 1999;5: 110-23.
17. The committee for The Japanese Respiratory Society guidelines for the management of respiratory infections. Guidelines for the management of community acquired pneumonia in adults, revised ed. Respirology 2006;11(Suppl. 3):S79-133.
18. Saito A, Kohno S, Matsushima T, Watanabe A, Oizumi K, Yamaguchi K, et al. Prospective multicenter study of the causative organisms of communityacquired pneumonia in adults in Japan. J Infect Chemother 2006;12: 63-9.
19. Chiu LM, Menhinick AM, Johnson PW, Amsden GW. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J Antimicrob Chemother 2002;50: 1075-9.
20. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003;47: 2450-7.
21. Fukuda Y, Yanagihara K, Higashiyama Y, Miyazaki Y, Hirakata Y, Mukae H, et al. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 2006;27: 1020-5.
22. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012;68: 479-503.
23. Klugman KP, Lonks Jr. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 2005;11: 802-7.
24. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998;92: 1032-9.
25. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho- Mentero J, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010;36: 612-20.
26. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, et al. Macrolidebased regimens and mortality in hospitalized patients with communityacquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012. http://dx.doi.org/10.1093/cid/cis414.